In the United States alone, 1 out of 3 adult individuals are obese. This makes them especially vulnerable to serious types of diseases like type 2 diabetes, heart ailments and many other obesity related illnesses. Belviq is a revolutionary medication especially designed for weight control proven in helping people lose weight. Belviq is the trade name of a product named Lorcaserin. It was developed by Arena Pharmaceuticals and it has undergone years of clinical testing to the point there the FDA approved it for the treatment of obesity. It generally works by stimulating areas of the brain that's connected to your appetite.
This drug specifically works in a particular neurotransmitter called Serotonin which is located exclusively in the choroid plexus, hippocampus, cerebellum, amygdale, thalamus, hypothalamus, and cortex. These parts are all sub-parts of the human brain. The activation of neurotransmitters in the hypothalamus stimulates a person's appetite. The more serotonin that it produces, the more likely will a person crave for food. Serotonin greatly affects a person's mood and food cravings. Presently, the exact mechanism for appetite stimulation is not yet known. But simple laboratory experiments conducted by scientists around the world show that serotonin has significant role in influencing a person's appetite in one way or another.
Today, a lot of research work is being conducted to address the increasing concerns about obesity. In a trial examination conducted by a group of scientists in MIT, Lorcaserin showed promising results as it specifically targets the serotonin neurotransmitter in the brain; this, in effect, effectively regulates hunger. Taking the pills means that obese people will feel less hungry, thus promoting weight loss by eating less.
There are many drugs similar to Lorcaserin. One such drug is Fenfluramine. This drug also targets the serotonin receptor; however, this drug was removed from the market due to its dangerous side effects. Clinical tests showed that Fenfluramine affects the functionality of the heart valves when taken internally. However Lorcaserin has not been associated to these side effects. In a two-year study, a total of 3,000 overweight patients were tested and after one year, 50 percent of the patients who took Lorcaserin lost an average of 5 percent of their body weight and achieved the FDA requirements for the definition of an obesity fighting drug.
Belviq is generally safe despite the side effects that were noted; they were proven to be mild and tolerable. Results of tests show that 7 percent of the participating patients in both Lorcaserin and Placebo drug dropped out due to side effects. This 7 percent drop off rate is considered minimal by Arena (makers of Lorcaserin). Lorcaserin had the lowest discontinuation rate mainly because it is the only drug that has few side effects in comparison to other drugs with similar functions.
Belviq produces minimal side-effects in human subjects according to clinical trials conducted by Arena. The rate in which Lorcaserin produces its side effects is significantly low compared to other drugs. The most noted side-effect of Lorcaserin is a slight headache, which is experienced by 18 percent of the total trial participants. Other side effects of the treatment include anxiety and depression.
These side-effects are frequently and are commonly reported by trial patients participating in both the Lorcaserin tests and Placebo tests. On December 15, 2010, it was reported that Lorcaserin was associated with the development of a certain kind of cancer in laboratory rats. However, this claim was not backed with sufficient data became a non issue later on.
On June 27th, 2012, after several months of research conducted by Arena, FDA finally approved the prescription of Lorcaserin for individuals suffering from obesity, The restrictions generally prohibit the use of Lorcaserin to patients with a BMI under 30. However some there could be exceptions for people with weight related health problems or for other ailments. The same restrictions apply for patients who have high blood pressure or undergoing Type 2 Diabetes treatments.
Researchers have also considered Lorcaserin aimed for people diagnosed with Type 2 Diabetes. Their study was published in a journal in March 2012. The journal was entitled Obesity and is one of the most informative journals on the said health condition. The study consisted of 604 trial patients who have been diagnosed with Type 2 Diabetes and who took Lorcaserin medications for a year. At the end of the study, they came up with the following results:
"5 percent of the trial patients taking 10 milligrams of Lorcaserin, twice per day, lost at least 5 percent of their total body weight.
"7 percent of the trial patients taking 10 milligrams of Lorcaserin, one tablet a day, lost at least 5 percent of their total body weight, and
"1 percent of the trial patients taking a Placebo lost at least 5 percent of their total body weight.
To summarize, the average weight loss of trial patients who took Belviq® (Lorcaserin) showed considerable weight loss with minimal side effects. As a result the FDA has approved this medication for the treatment of obesity. Belviq will soon be available via a doctors prescription and will benefit many who suffer from being overweight.
Belviq® the new FDA approved Prescription Diet Pill